BG-9928 (Biogen Idec)

Curr Opin Investig Drugs. 2005 Sep;6(9):962-8.

Abstract

Biogen Idec, under license from CV Therapeutics, is developing BG-9928, a selective oral adenosine A, receptor antagonist, for the potential treatment of congestive heart failure. By January 2003, phase II trials of BG-9928 were ongoing.

MeSH terms

  • Adenosine A1 Receptor Antagonists*
  • Animals
  • Clinical Trials as Topic
  • Diuretics / therapeutic use*
  • Heart Failure / drug therapy*
  • Humans
  • Structure-Activity Relationship
  • Xanthines / chemical synthesis
  • Xanthines / metabolism
  • Xanthines / pharmacology
  • Xanthines / therapeutic use*

Substances

  • Adenosine A1 Receptor Antagonists
  • BG 9928
  • Diuretics
  • Xanthines